X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GLENMARK PHARMA JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
 
P/E (TTM) x 20.7 14.1 146.7% View Chart
P/BV x 4.4 3.9 111.3% View Chart
Dividend Yield % 0.4 0.3 128.6%  

Financials

 JUBILANT LIFE SCIENCES   GLENMARK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
GLENMARK PHARMA
Mar-16
JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1871,262 14.8%   
Low Rs65672 9.7%   
Sales per share (Unadj.) Rs364.3270.6 134.7%  
Earnings per share (Unadj.) Rs6.824.9 27.5%  
Cash flow per share (Unadj.) Rs24.534.4 71.2%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %2.40.2 1,151.3%  
Book value per share (Unadj.) Rs164.9151.3 109.0%  
Shares outstanding (eoy) m159.28282.16 56.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.6 9.7%   
Avg P/E ratio x18.438.9 47.3%  
P/CF ratio (eoy) x5.128.1 18.3%  
Price / Book Value ratio x0.86.4 12.0%  
Dividend payout %43.88.0 545.1%   
Avg Mkt Cap Rs m20,061272,778 7.4%   
No. of employees `0006.210.0 61.7%   
Total wages/salary Rs m11,05213,782 80.2%   
Avg. sales/employee Rs Th9,383.07,614.9 123.2%   
Avg. wages/employee Rs Th1,786.91,374.8 130.0%   
Avg. net profit/employee Rs Th176.3700.2 25.2%   
INCOME DATA
Net Sales Rs m58,03476,340 76.0%  
Other income Rs m191356 53.5%   
Total revenues Rs m58,22476,696 75.9%   
Gross profit Rs m5,78614,172 40.8%  
Depreciation Rs m2,8122,691 104.5%   
Interest Rs m3,2371,789 181.0%   
Profit before tax Rs m-7210,048 -0.7%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6963,028 23.0%   
Profit after tax Rs m1,0907,019 15.5%  
Gross profit margin %10.018.6 53.7%  
Effective tax rate %-965.930.1 -3,204.6%   
Net profit margin %1.99.2 20.4%  
BALANCE SHEET DATA
Current assets Rs m29,28059,096 49.5%   
Current liabilities Rs m38,91240,018 97.2%   
Net working cap to sales %-16.625.0 -66.4%  
Current ratio x0.81.5 51.0%  
Inventory Days Days8475 112.6%  
Debtors Days Days51119 42.5%  
Net fixed assets Rs m55,71239,075 142.6%   
Share capital Rs m155282 54.7%   
"Free" reserves Rs m20,96830,281 69.2%   
Net worth Rs m26,26542,703 61.5%   
Long term debt Rs m17,16924,873 69.0%   
Total assets Rs m88,606111,026 79.8%  
Interest coverage x1.06.6 14.8%   
Debt to equity ratio x0.70.6 112.2%  
Sales to assets ratio x0.70.7 95.3%   
Return on assets %4.97.9 61.6%  
Return on equity %4.216.4 25.3%  
Return on capital %11.617.5 66.0%  
Exports to sales %37.843.3 87.3%   
Imports to sales %16.57.4 221.9%   
Exports (fob) Rs m21,93333,044 66.4%   
Imports (cif) Rs m9,5675,672 168.7%   
Fx inflow Rs m22,00436,945 59.6%   
Fx outflow Rs m11,74961,066 19.2%   
Net fx Rs m10,255-24,122 -42.5%   
CASH FLOW
From Operations Rs m8,0263,449 232.7%  
From Investments Rs m-1,744-8,802 19.8%  
From Financial Activity Rs m-4,4476,986 -63.7%  
Net Cashflow Rs m1,834934 196.4%  

Share Holding

Indian Promoters % 45.6 48.3 94.4%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 6.9 126.1%  
FIIs % 21.2 34.4 61.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 56,727 42.0%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Margins under Pressure (Quarterly Results Update - Detailed)

Jun 22, 2016

Glenmark has announced its 4QFY16 results. The company has reported 30.5% YoY growth in sales and 1255.8% YoY increase in net profits. Here is our analysis of the results.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 17, 2017 03:37 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS